Clinical Trial Results:
Title: Phase 3 study investigating the efficacy and safety of TAVT-45 (abiraterone acetate) granules for oral Suspension (a novel abiraterone acetate formulation) relative to a reference abiraterone acetate formulation in patients with metastatic castrate sensitive prostate cancer (mCSPC) and metastatic castrate resistant prostate cancer (mCRPC).
Trial design: This was a Phase 3, multi-national, randomised, open-label, parallel-group study to establish therapeutic equivalence between TAVT-45 and the currently marketed version of abiraterone acetate, Zytiga (R-AA) in patients with mCRPC and high-risk mCSPC. 108 patients (54 patients per prostate cancer population) were to be randomized (1:1) to either oral TAVT-45 or oral R-AA. Randomization was stratified by prostate cancer population (CRPC vs CSPC) and screening serum testosterone level (<10 vs >=10 ng/dL). The study consisted of a 28-day screening period, an 84-day treatment period, and a 7-day follow-up period. 107 patients were randomised and 103 patients were treated (TAVT-45: 54; R-AA: 49).
Patients randomised to TAVT-45 were treated with 250 mg of TAVT-45 (reconstituted in water or fruit juice) twice daily (BID). Patients randomized to R-AA were treated with 2 x 500 mg tablets once daily (QD). Patients in both groups also took prednisone (5 mg once or twice daily, depending on prostate cancer population).
The median duration of treatment for all patients was 84.0 days (range: 1 to 87 days) and was similar for both treatment groups.
The primary endpoint was the comparison of the average of rounded-up serum testosterone levels on Days 9 and 10 between TAVT-45 and R-AA. TAVT-45 and R-AA were compared based on the equivalence approach of determining the 90% confidence interval (CI) of the test-to-reference geometric mean ratio (GMR) within the 80% to 125% equivalence limit when analyzed on a log scale (natural logarithms).
Summary
|
|
EudraCT number |
2020-005611-46 |
Trial protocol |
FR SE HU ES |
Global end of trial date |
20 Oct 2022
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 Jul 2023
|
First version publication date |
15 Jul 2023
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
TAVT45C02
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04887506 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Tavanta Therapeutics, Inc.
|
||
Sponsor organisation address |
1000 First Avenue, Suite 405, King of Prussia, Upper Merion Township, United States, PA 19406
|
||
Public contact |
Tavanta, Tavanta Therapeutics, Inc., +1 833776 8963, info@tavanta.com
|
||
Scientific contact |
Tavanta, Tavanta Therapeutics, Inc., +1 833776 8963, info@tavanta.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
31 Mar 2023
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
20 Oct 2022
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
20 Oct 2022
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Establish therapeutic equivalence between TAVT-45 granules and Zytiga tablets in patients with mCRPC or high-risk mCSPC.
|
||
Protection of trial subjects |
The trial was carried out in compliance with the protocol, in accordance with the principles of the Declaration of Helsinki, in accordance with GCP as described in ICH Guideline E6 (R2), and with all relevant laws and applicable regulatory requirements. An independent Data Monitoring Committee (DMC) was also established to review safety data collected during the conduct of the study and monitor the progress of the study.
|
||
Background therapy |
In addition to TAVT-45 or R-AA, all patients were to take oral prednisone: 5 mg BID for mCRPC patients, and 5 mg QD for mCSPC patients. This requirement for co-administration of prednisone (including the dose level and frequency) was consistent with the on-label dosing requirements for R-AA. | ||
Evidence for comparator |
Zytiga is the currently approved and marketed version of abiraterone acetate. It decreases serum testosterone and other androgens to levels lower than those achieved by the use of GnRH analogues alone or by orchiectomy due to the selective inhibition of the CYP17 enzyme required for androgen biosynthesis. | ||
Actual start date of recruitment |
05 May 2021
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Poland: 7
|
||
Country: Number of subjects enrolled |
Spain: 38
|
||
Country: Number of subjects enrolled |
Sweden: 5
|
||
Country: Number of subjects enrolled |
United Kingdom: 16
|
||
Country: Number of subjects enrolled |
France: 4
|
||
Country: Number of subjects enrolled |
Hungary: 9
|
||
Country: Number of subjects enrolled |
United States: 24
|
||
Worldwide total number of subjects |
103
|
||
EEA total number of subjects |
63
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
13
|
||
From 65 to 84 years |
80
|
||
85 years and over |
10
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
Patients age ≥18 years, with pathologically-confirmed adenocarcinoma of the prostate, ongoing therapy with a GnRH agonist or antagonist (unless patient had already had a bilateral orchiectomy), and had either metastatic castration-resistant prostate cancer (mCRPC) or high-risk metastatic castration-sensitive prostate cancer (mCSPC) . | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
Screening was up to 28 days before first dosing, when medical history, physical examination, serum testosterone, vital signs, and clinical laboratory data were collected. Upon meeting all inclusion/exclusion criteria set forth in the protocol, patients were randomized in a 1:1 fashion to receive TAVT-45 or R-AA. | ||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
Overall study (overall period)
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||
Blinding implementation details |
This was an open-label study.
|
||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
TAVT-45 | ||||||||||||||||||||||||
Arm description |
Patients with mCRPC or high-risk mCSPC randomised and treated with at least one dose of TAVT-45. This was the TAVT-45 group of the mITT population. | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
TAVT-45
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Granules for oral suspension
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
The dose in this study was 250 mg BID (total daily dose 500 mg). For each 250 mg dose, 1 granule sachet had to be reconstituted in tap water or specified juice (orange juice) and the resulting suspension immediately taken orally.
|
||||||||||||||||||||||||
Arm title
|
R-AA | ||||||||||||||||||||||||
Arm description |
Patients with mCRPC or high-risk mCSPC treated with at least one dose of reference abiraterone acetate (R-AA) (Zytiga). This was the R-AA group of the mITT population. | ||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||
Investigational medicinal product name |
R-AA
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
Zytiga
|
||||||||||||||||||||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||
Dosage and administration details |
The daily dose in this study was 1000 mg (2 x 500 mg tablets) administered QD (i.e., as a single daily dose).
|
||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
TAVT-45
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients with mCRPC or high-risk mCSPC randomised and treated with at least one dose of TAVT-45. This was the TAVT-45 group of the mITT population. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
R-AA
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients with mCRPC or high-risk mCSPC treated with at least one dose of reference abiraterone acetate (R-AA) (Zytiga). This was the R-AA group of the mITT population. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
TAVT-45
|
||
Reporting group description |
Patients with mCRPC or high-risk mCSPC randomised and treated with at least one dose of TAVT-45. This was the TAVT-45 group of the mITT population. | ||
Reporting group title |
R-AA
|
||
Reporting group description |
Patients with mCRPC or high-risk mCSPC treated with at least one dose of reference abiraterone acetate (R-AA) (Zytiga). This was the R-AA group of the mITT population. | ||
Subject analysis set title |
TAVT-45 CR-ITT
|
||
Subject analysis set type |
Modified intention-to-treat | ||
Subject analysis set description |
The mCRPC Intention-to-treat (CR-ITT) population was defined as a subset of the mITT population and included all randomised patients who had mCRPC, and this reporting group included patients randomised to TAVT-45.
|
||
Subject analysis set title |
TAVT-45 CS-ITT
|
||
Subject analysis set type |
Modified intention-to-treat | ||
Subject analysis set description |
The mCSPC Intention-to-treat (CS-ITT) population was defined as a subset of the mITT population and included all randomised patients who had mCSPC, and this reporting group included patients randomised to TAVT-45
|
||
Subject analysis set title |
R-AA CR-ITT
|
||
Subject analysis set type |
Modified intention-to-treat | ||
Subject analysis set description |
The mCRPC Intention-to-treat (CR-ITT) population was defined as a subset of the mITT population and included all randomised patients who had mCRPC, and this reporting group included patients randomised to R-AA.
|
||
Subject analysis set title |
R-AA CS-ITT
|
||
Subject analysis set type |
Modified intention-to-treat | ||
Subject analysis set description |
The mCSPC Intention-to-treat (CS-ITT) population was defined as a subset of the mITT population and included all randomised patients who had mCSPC, and this reporting group included patients randomised to R-AA.
|
|
|||||||||||||
End point title |
Serum testosterone (ng/dL) Days 9 and 10 average (rounded-up), CR-ITT [1] | ||||||||||||
End point description |
The primary endpoint was the between-group comparison of average (rounded-up) serum testosterone for the Days 9 and 10 for mCRPC patients treated with either TAVT-45 or R-AA.
The equivalence ANCOVA model (using the natural logarithm scale) had treatment as an independent variable and the stratification factor, screening testosterone (<10 vs ≥10 ng/dL), as covariate. If the 90% CI fell within the recommended 0.800-1.250 limits of equivalence when analyzed on a natural log scale, then treatments were therapeutically equivalent based on rounded-up average Days 9 and 10 testosterone levels.
This primary analysis of therapeutic equivalence of TAVT-45 and R-AA resulted in a geometric mean ratio (GMR) of 1.000; the 90% CI of GMR was not evaluable.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
From baseline to Days 9 and 10.
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Since the 90% CIs for GMR were not evaluable, these data could not be entered into the statistical analysis section. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
PSA-50 response rate, mITT | |||||||||
End point description |
A PSA-50 responder was defined as a patient with a decrease of >=50% in PSA levels from baseline at any time up to or on Day 84. The mITT population included mCRPC and mCSPC patients.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
From baseline to Day 84.
|
|||||||||
|
||||||||||
Statistical analysis title |
Odds ratio | |||||||||
Statistical analysis description |
Odds ratio generated using the Wald method.
|
|||||||||
Comparison groups |
TAVT-45 v R-AA
|
|||||||||
Number of subjects included in analysis |
103
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
equivalence | |||||||||
P-value |
= 0.3408 | |||||||||
Method |
Regression, Logistic | |||||||||
Parameter type |
Odds ratio (OR) | |||||||||
Point estimate |
1.69
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
0.574 | |||||||||
upper limit |
4.979 |
|
|||||||||||||
End point title |
Serum testosterone (ng/dL) Days 9 and 10 average (rounded-up), CS-ITT | ||||||||||||
End point description |
This was a supplementary analysis of equivalence, with a between group comparison of serum testosterone for the Days 9 and 10 average (rounded-up) values for mCSPC patients treated with either TAVT-45 or R-AA.
|
||||||||||||
End point type |
Other pre-specified
|
||||||||||||
End point timeframe |
Baseline to Day 9 and 10.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Equivalence of TAVT 45 and R-AA - CS-ITT | ||||||||||||
Statistical analysis description |
Equivalence ANCOVA model (using the natural logarithm scale) with treatment as an independent variable and the stratification factor, screening testosterone (<10 vs >=10 ng/dL), as covariate.
|
||||||||||||
Comparison groups |
TAVT-45 CS-ITT v R-AA CS-ITT
|
||||||||||||
Number of subjects included in analysis |
40
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence [2] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Geometric mean ratio | ||||||||||||
Point estimate |
0.975
|
||||||||||||
Confidence interval |
|||||||||||||
level |
90% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.944 | ||||||||||||
upper limit |
1.007 | ||||||||||||
Notes [2] - If the 90% CI fell within the recommended 0.800-1.250 limits of equivalence when analyzed on a natural log scale, then treatments were therapeutically equivalent based on rounded-up average Days 9 and 10 testosterone levels. |
|
|||||||||||||
End point title |
Serum testosterone (ng/dL) Days 9 and 10 average (rounded-up), mITT | ||||||||||||
End point description |
Supplementary analysis of equivalence of TAVT-45 and R-AA on Days 9 and 10 average (rounded-up) values in the mITT population (including mCRPC and mCSPC patients).
|
||||||||||||
End point type |
Other pre-specified
|
||||||||||||
End point timeframe |
From baseline to Day 9 and 10.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Equivalence of TAVT 45 and R-AA, mITT | ||||||||||||
Statistical analysis description |
Equivalence ANCOVA model (using the natural logarithm scale) with treatment as an independent variable and the stratification factor, screening testosterone (<10 vs >=10 ng/dL), as covariate.
|
||||||||||||
Comparison groups |
TAVT-45 v R-AA
|
||||||||||||
Number of subjects included in analysis |
103
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence [3] | ||||||||||||
Method |
ANCOVA | ||||||||||||
Parameter type |
Geometric mean ratio | ||||||||||||
Point estimate |
0.99
|
||||||||||||
Confidence interval |
|||||||||||||
level |
90% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.978 | ||||||||||||
upper limit |
1.002 | ||||||||||||
Notes [3] - If the 90% CI fell within the recommended 0.800-1.250 limits of equivalence when analyzed on a natural log scale, then treatments were therapeutically equivalent based on rounded-up average Days 9 and 10 testosterone levels. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From baseline to end of treatment and follow-up period.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
24.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
TAVT-45
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients with mCRPC and high-risk mCSPC treated with at least one dose of TAVT-45. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
R-AA
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Patients with mCRPC or high-risk mCSPC treated with at least one dose of reference abiraterone acetate (R-AA) (Zytiga). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
28 Jan 2021 |
Amendment 1:
Text was added to provide guidance on toxicity management during this study related to hepatotoxicity and CTCAE grade ≥ 3 toxicities, in alignment with Zytiga prescribing information.
Text was added to clarify that ALT or AST rises above 5x the upper limit of normal (ULN), or total bilirubin rises above 3x ULN, at any time during the study would result in permanent discontinuation of study medication.
|
||
26 Mar 2021 |
Amendment 2:
Inclusion criterion #10 was updated to exclude herbal supplements only.
Uncontrolled hypertension was defined for Exclusion criterion #13.
A new exclusion criterion (#18) was added regarding post-trial treatment.
Text was added to clarify timing of randomisation, which had to occur before Day 1, but after confirming eligibility and receiving screening testosterone values due to just-in-time shipping of study medication.
Clarifications on concomitant medication that should be used with caution were added.
Text was added to note that additional patients could be randomised to ensure that 108 patients were treated through Day 9 for collection of the primary endpoint data.
The definition of the Per Protocol population was clarified.
Added list of notable strong CYP3A4 inducers
Added text to clarify the provision of post-trial treatment, including no post-trial access to study medication, and the definition of “End of Trial”
Added/revised text to better describe timing and information needed for reporting AEs, SAEs, suspected unexpected serious adverse reactions (SUSARs) and partner pregnancies
Added text to explicitly state source data should also be readily available upon any request from the authorities
|
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |